United Therapeutics Corporation (UTHR)
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark
UTHR beats Q3 earnings forecasts on solid Tyvaso and Orenitram growth, while revenues fall shy of estimates.
United Therapeutics Corporation (UTHR) Q3 2025 Earnings Call Transcript
United Therapeutics Corporation ( UTHR ) Q3 2025 Earnings Call October 29, 2025 9:00 AM EDT Company Participants Harrison Silvers - Manager of Investor Relations Martine Rothblatt - Founder, Chairman & CEO Michael Benkowitz - President & COO Leigh Peterson - Executive Vice President of Product Development & Xenotransplantation Patrick Poisson - Executive VP of Technical Operations Conference Call Participants Lisa Walter - RBC Capital Markets, Research Division Andreas Argyrides - Oppenheimer & Co. Inc., Research Division Joseph Thome - TD Cowen, Research Division Olivia Brayer - Cantor Fitzgerald & Co., Research Division Jiale Song - Jefferies LLC, Research Division Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division Presentation Operator Good morning, everyone, and welcome to the United Therapeutics Corporation Third Quarter 2025 Corporate Update. My name is Jamie, and I will be your conference operator today.
Compared to Estimates, United Therapeutics (UTHR) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
United Therapeutics (UTHR) Beats Q3 Earnings Estimates
United Therapeutics (UTHR) came out with quarterly earnings of $7.16 per share, beating the Zacks Consensus Estimate of $6.89 per share. This compares to earnings of $6.39 per share a year ago.
United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is IPF the Next Big Market Opportunity for United Therapeutics?
UTHR reports strong TETON-2 results for Tyvaso in IPF, showing lung function gains and eyeing a major new market.
United Therapeutics Corporation - Special Call
United Therapeutics Corporation - Special Call Company Participants Harrison Silvers - Manager of Investor Relations Leigh Peterson - Executive Vice President of Product Development & Xenotransplantation Martine Rothblatt - Founder, Chairman & CEO Conference Call Participants Steven D. Nathan Olivia Brayer - Cantor Fitzgerald & Co., Research Division Andreas Argyrides - Oppenheimer & Co. Inc., Research Division Joseph Thome - TD Cowen, Research Division Lisa Walter - RBC Capital Markets, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Jason Gerberry - BofA Securities, Research Division Presentation Operator Good afternoon, and welcome to the United Therapeutics Corporation Phase 3 TETON-2 Results Conference Call.
United Therapeutics Corporation (UTHR) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
United Therapeutics Corporation (NASDAQ:UTHR ) Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 1:10 PM EDT Company Participants Harrison Silvers Martine Rothblatt - Founder, Chairman & CEO James Edgemond - CFO & Treasurer Conference Call Participants William Pickering - Sanford C. Bernstein & Co., LLC.
UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals
United Therapeutics hit a record high after its Tyvaso study in idiopathic pulmonary fibrosis met key goals and showed broad patient benefits.
United Therapeutics: Is UTHR Stock Still A Buy At $400?
United Therapeutics' stock (NASDAQ: UTHR) surged 33% on September 2nd after the company announced positive late-stage clinical trial results for Tyvaso (treprostinil) Inhalation Solution in idiopathic pulmonary fibrosis (IPF). The trial met its primary endpoint, and the treatment showed good tolerability with a safety profile consistent with prior Tyvaso studies.
United Therapeutics shares jump on positive lung disease study results
United Therapeutics Corporation (NASDAQ:UTHR) shares surged more than 35% following the release of positive late-stage clinical trial results for its lung disease drug Tyvaso. The company said its TETON-2 study evaluating nebulized Tyvaso in patients with idiopathic pulmonary fibrosis (IPF) met its primary endpoint, showing significant improvements in lung function compared with placebo over a 52-week period.
